Tesamorelin Before and After: What the Visceral-Fat Trials Measured

The short version

When people search "tesamorelin before and after" they usually want pictures. This page gives numbers instead, because that is what the trials produced. The before-and-after that matters is a CT or MRI measurement of visceral fat (the deep belly fat around the organs), and across the pivotal trial it dropped 15.2% in 26 weeks while placebo went up 5.0% ^[1]. Triglycerides fell, IGF-1 rose, and liver fat dropped in a separate study ^[1][3]. Two honest caveats the data is firm on: every result is from people with HIV-related fat buildup, and the fat comes back when dosing stops ^[2][6].

Tesamorelin results: measured outcomes across trials

The tesamorelin results that anchor the record are imaging-based fat measurements, not scale weight. In the pivotal 26-week Phase 3 RCT of 412 HIV patients with abdominal fat accumulation, tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% while placebo rose 5.0%; triglycerides decreased 50 mg/dL (vs +9 mg/dL placebo) and IGF-1 increased 81.0% ^[1]. Over the 52-week program the VAT reduction was sustained at -18% versus baseline, and changes in glucose parameters over the year were not clinically significant ^[2].

The pooled odds tell the same story: across two Phase 3 RCTs (543 tesamorelin vs 263 placebo), the odds of reducing VAT below 140 cm² were 3.9-fold greater with tesamorelin (95% CI 2.03–7.44); baseline metabolic syndrome, triglycerides >1.7 mmol/L, and white race predicted response ^[10]. The 2026 meta-analysis of five RCTs pooled the effect at -27.71 cm² visceral fat, -1.18 kg trunk fat, -4.28% hepatic fat, and +1.42 kg lean mass ^[13]. These are the visceral-fat trial results in aggregate — measured, pooled, and bounded by the population they came from.

Selective for visceral fat — and the liver

The before-and-after signature is selectivity. Tesamorelin reduced visceral adipose tissue (the fat around the organs) without significantly changing subcutaneous fat (the fat beneath the skin) or BMI in the studied trials ^[1]. It also improved fat quality: over 26 weeks it raised VAT and SAT density on CT (VAT +6.2 vs +0.3 HU placebo; SAT +4.0 vs +0.3 HU; both P<0.0001), an adipocyte-quality gain independent of fat-quantity change ^[9].

In HIV-associated fatty liver, the JAMA RCT recorded a -42 cm² visceral-fat treatment effect (P=0.005) alongside a net -2.9% hepatic-fat reduction (P=0.003) ^[3]. The metabolic dividend was proportional to the fat loss: responders who hit at least 8% VAT reduction showed greater triglyceride reductions and a better metabolic profile than non-responders ^[7], and the inflammatory-marker improvements tracked VAT reduction rather than a direct GH effect ^[8]. The body-composition picture is a redistribution — visceral and hepatic fat down, lean mass modestly up ^[13] — not a generalized weight-loss result.

The before-and-after that is not on a scale

Because tesamorelin reduces visceral fat without significantly changing BMI ^[1], the most informative "before and after" is metabolic, not the bathroom scale. Triglycerides fell 50 mg/dL in the pivotal trial against a 9 mg/dL rise on placebo ^[1], and the responders who achieved at least 8% VAT reduction showed the largest triglyceride improvements and the most favorable overall metabolic profile ^[7].

The inflammatory "after" is subtler but consistent: tesamorelin reduced tissue plasminogen activator antigen and modestly raised adiponectin, with the inflammatory-marker changes tracking the degree of VAT reduction rather than a direct GH effect — evidence that visceral fat is the mediator, not a bystander ^[8]. The 2023 post-hoc analysis added that the VAT and waist-circumference reductions held regardless of whether patients had dorsocervical fat accumulation (P=0.657), so the before-and-after did not depend on that subgroup feature ^[12]. The honest reading is a metabolic redistribution captured by imaging and bloodwork, bounded by the HIV-lipodystrophy population it was measured in.

How long does it take, and what happens when you stop?

The trials measured visceral-fat reduction over 26 weeks, with reduction sustained at 52 weeks on continued dosing ^[1][2]. The 2026 five-RCT meta-analysis pooled visceral, trunk, and hepatic-fat changes across these multi-month treatment periods ^[13]. There is no published evidence for a rapid, weeks-scale cosmetic transformation; the effect is a months-long shift measured by imaging.

The durability caveat is firm and repeatedly documented. In the 52-week program, visceral fat reaccumulated upon discontinuation ^[2], and the Phase 3 trial with a safety extension likewise reported reversal of the visceral-fat reduction after stopping ^[6]. The measured benefit was contingent on continued dosing — the "after" reverts toward the "before" once the drug is withdrawn. Any general-population fat-loss extrapolation also carries an honest gap: no large general-population fat-loss RCT has been completed, so non-HIV efficacy is mechanistically plausible but not established ^[4].